Xenon Pharmaceuticals reported a robust Phase 3 win for azetukalner in focal onset seizures, delivering placebo‑adjusted seizure reductions substantially above expectations. The company said it will pursue an FDA submission in the third quarter, positioning the KV7 potassium channel opener as a potential new oral standard of care. Results showed dose-dependent efficacy and an acceptable tolerability profile, with dizziness the most common adverse event. Investors reacted strongly to the readout, sending Xenon shares sharply higher and improving the company’s funding runway for a regulatory push. The dataset—announced in corporate releases and covered broadly by industry press—supports a rapid path to filing and commercialization planning. Clinicians and competitors will watch dose selection closely because adverse events increased at the higher dose, shaping commercial positioning and label strategy.